SLS Projected Dividend Yield

SELLAS Life Sciences Group Inc ( NASDAQ : SLS )

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing cancer immunotherapeutics for a range of cancer indications. Co.'s product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Co.'s primary product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms tumor 1 protein, which is present in 20 or more cancer types. NPS is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 expressing cancers.

20 YEAR PERFORMANCE RESULTS

SLS Dividend History Detail
SLS Dividend News
SLS Competitors News
# of Shares: 0 Closing Price: 0.87 Current Market Value: 0.00 Cost Basis: 0.00 Date Acquired:
Dividend Cash Flow
Year Annual Dividend Dividend Growth # of Shares Annual Dividend Income Yield On Cost %
2014 0.00 0% 0 $ 0.00 0.00%
2015 0.00 0% 0 $ 0.00 0.00%
2016 0.00 0% 0 $ 0.00 0.00%
2017 0.00 0% 0 $ 0.00 0.00%
2018 0.00 0% 0 $ 0.00 0.00%
2019 0.00 0% 0 $ 0.00 0.00%
2020 0.00 0% 0 $ 0.00 0.00%
2021 0.00 0% 0 $ 0.00 0.00%
2022 0.00 0% 0 $ 0.00 0.00%
2023 0.00 0% 0 $ 0.00 0.00%
2024 0.00 0% 0 $ 0.00 0.00%
2025 0.00 0% 0 $ 0.00 0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection)
0.00
Year
Declaration Date
Ex-Dividend Date
Record Date
Payable Date
Dividend $ Amount
Total:
0.0000
X
Search Dividend Investor